Hexagon Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Hexagon Capital Partners's BMY Position: Q2 2026 in Review
Hexagon Capital Partners increased its Bristol-Myers Squibb (BMY) stake by 6.8% in Q2 2026, buying an estimated $67.3K and bringing the position to 18,323 shares worth $1.06M. The position accounts for 0.15% of the portfolio, ranked #74.
Hexagon Capital Partners first reported a position in BMY in Q3 2020 and has held it in 24 quarters since. The position peaked at $1.09M in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Hexagon Capital Partners held 18,323 shares of Bristol-Myers Squibb worth $1.06M as of Q2 2026.
- Hexagon Capital Partners bought 1,172 Bristol-Myers Squibb shares in Q2 2026, an estimated $67.3K.
- Bristol-Myers Squibb made up 0.15% of Hexagon Capital Partners's portfolio in Q2 2026, its #74 holding.
- Hexagon Capital Partners first reported a position in Bristol-Myers Squibb in Q3 2020 and has held it in 24 quarters since.
- Hexagon Capital Partners's Bristol-Myers Squibb position peaked at $1.09M in Q1 2025.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Hexagon Capital Partners's 13F filing for Q2 2026, filed 7 Aug 2026.